Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

Original publication

DOI

10.1093/annonc/mdm201

Type

Journal article

Journal

Ann Oncol

Publication Date

12/2007

Volume

18

Pages

1927 - 1934

Keywords

Antineoplastic Agents, Breast Neoplasms, Chemotherapy, Adjuvant, Combined Modality Therapy, Gene Expression Profiling, Humans, Practice Guidelines as Topic